Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
7.83
-0.29 (-3.57%)
At close: Sep 12, 2025, 4:00 PM EDT
7.98
+0.15 (1.92%)
After-hours: Sep 12, 2025, 5:05 PM EDT
Gyre Therapeutics Revenue
Gyre Therapeutics had revenue of $26.77M in the quarter ending June 30, 2025, with 6.13% growth. This brings the company's revenue in the last twelve months to $102.19M, down -8.42% year-over-year. In the year 2024, Gyre Therapeutics had annual revenue of $105.76M, down -6.78%.
Revenue (ttm)
$102.19M
Revenue Growth
-8.42%
P/S Ratio
6.63
Revenue / Employee
$176,492
Employees
579
Market Cap
711.17M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 105.76M | -7.69M | -6.78% |
Dec 31, 2023 | 113.45M | 11.16M | 10.91% |
Dec 31, 2022 | 102.29M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGYRE News
- 8 days ago - Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 18 days ago - Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker - Benzinga
- 22 days ago - Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors - GlobeNewsWire
- 4 weeks ago - Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update - GlobeNewsWire
- 3 months ago - Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - GlobeNewsWire
- 3 months ago - Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 4 months ago - Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock - GlobeNewsWire
- 4 months ago - Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock - GlobeNewsWire